Rongcan Biopharma Secures Over RMB 100 Million in Series A Financing and Earns Multiple Industry Accolades

Recently,Rongcan Biotech, a Platform Enterprise with Independent Innovation in Nucleic Acid Technology, Completes Business Registration Changes for Its Over RMB 100 Million Series A Financing Round。This round of financing was led by Yuexiu Industrial Fund, with participation from Shaanxi Growth Fund, Zhangjiagang Jintai Jinhong Fund, and Huafang Capital.This round of financing will help Rongcan Biomedical accelerate product development and team building, and advance its leading pipeline into clinical trials.. In November, Rongcan Biomedical was listed on the “2023 China Biopharmaceutical Front-runners 100 List,” recognized as a Rising Star in Biopharmaceuticals, and simultaneously included in the Top 100 Discoveries of Innovation Value in China’s Pharmaceutical Industry for 2022–2023 at the 15th China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference.

Rongcan Biomedical is a full-chain R&D company dedicated to the development and industrialization of gene (nucleic acid) therapeutics. Its technical expertise spans nucleic acid sequence design and optimization, large-scale synthesis of mRNA drug substances, delivery vector design and preparation, as well as the design and development of nucleic acid drugs. The founding team boasts over a decade of experience in the nucleic acid industry and has successfully developed cationic lipid carriers with fully independent intellectual property rights. In collaboration with Professor Robert Langer, the team was granted a U.S. patent for novel cationic lipid carriers, making it one of the few teams in China to co-develop such carriers with Professor Langer and secure U.S. patent authorization. These cationic lipids have gained recognition from global experts in the field of nucleic acid delivery and have been utilized by multiple internationally renowned research teams for RNA drug delivery studies. Related findings have been published in top-tier international journals, including *Science Translational Medicine*, *Nature Biomedical Engineering*, *PNAS*, and *Science Advances*.

As an innovative nucleic acid drug R&D enterprise, Rongcan Biomedical has established a robust and comprehensive patent portfolio around its independently developed lipid nanoparticle (LNP) delivery technology. The company has achieved breakthrough progress in areas such as cationic lipid structures, formulation component ratios, therapeutic indications, and RNA sequences, securing multiple domestic patent grants and PCT patent applications. Its independently owned and commercially viable LNP delivery system has completed global freedom-to-operate (FTO) analyses, ensuring the right to operate freely worldwide. Leveraging its proprietary library of innovative cationic lipid compounds, Rongcan has conducted in vivo evaluation, screening, and optimization of nearly 10,000 self-synthesized lipid nanocarriers through animal studies. Preclinical head-to-head animal data demonstrate that Rongcan’s proprietary LNPs match or surpass those of leading international companies in terms of delivery efficiency, stability, safety, cost, and accessibility. Furthermore, the company has made breakthrough advances in novel formulations, including inhalable and lyophilized products, which hold broad application prospects.

Founder of Rongcan BiomedicalIt stated that, against the backdrop of the current financing market for innovative drugs, it is no small feat for Rongcan Biomedical Technology (Shanghai) Co., Ltd. to gain the recognition of investors in this round and secure over RMB 100 million in funding. We extend our gratitude to the investors in this round for their recognition of Rongcan’s core competitiveness and business model. Rongcan will live up to its mission by continuously strengthening and expanding its technological advantages in LNP delivery systems, fortifying its patent moat, pursuing steady operations, collaborating with more pharmaceutical companies for mutual development, and contributing to the R&D of nucleic acid, cell, and gene therapy drugs in China.

Lu Rong, Managing Partner and President of Yuexiu Industrial FundIt was stated that lipid nanoparticle (LNP) delivery systems, as one of the most commercially successful vectors, have been widely applied in multiple niche sectors including cell therapy, RNA therapeutics, and gene therapy, gaining extensive validation and recognition from numerous multinational corporations (MNCs) and CGT biotech companies. As a leading LNP R&D company, Rongcan Biomedical Technology (Shanghai) Co., Ltd. represents another strategic deep-dive investment by Guangzhou YUEXIU Industrial Investment Fund Management Co.,Ltd. in the CGT R&D industry chain. We are optimistic about Rongcan’s core technology R&D capabilities and its management team’s ability to drive commercialization. Rongcan is among the few domestic companies that have comprehensively broken through the patent barriers surrounding the four key components of LNPs, successfully establishing a robust patent moat and earning high recognition from many leading industry players. In the future, Guangzhou YUEXIU Industrial Investment Fund Management Co.,Ltd. will continue to practice empowerment-oriented investment and further deepen Rongcan’s industrial layout in the Pearl River Delta region.

Dr. Guo Jia, Managing Director of Shaanxi Growth FundIt stated that Rongcan Biomedical Technology (Shanghai) Co., Ltd. possesses a globally independent intellectual property rights-owned nano-delivery system, achieving precise extrahepatic targeting and specific cell-targeted delivery. This breakthrough addresses the critical bottleneck constraining nucleic acid drug development in China, serving as the cornerstone for its evolution into an international leader in innovative nucleic acid therapeutics. The Rongcan team has demonstrated outstanding capabilities in innovative R&D, business development, and efficient execution, forging deep collaborations with numerous major pharmaceutical companies and cell and gene therapy enterprises, thereby earning industry recognition. We look forward to working together with the company to make significant contributions to human health.

Zeng Li, Senior Vice President of Huafang CapitalIt was stated that the founding team of Rongcan Biomedical Technology (Shanghai) Co., Ltd. possesses both profound scientific research backgrounds and extensive industry experience. Building on its independently owned LNP platform technology, the team has keenly recognized shifts in market trends, rapidly initiating development collaborations around its pipeline and products within China, while steadily advancing the development and commercialization of its proprietary pipeline. The company’s demonstrated technological innovation capabilities and flexible, efficient business strategies are impressive, giving us full confidence in its ability to continuously deliver technologies and pipeline assets in the future mRNA drug development sector.